Table 3 Summary of studies with longitudinal follow-up of serum AMH levels in young girls undergoing chemotherapy (CT) for childhood cancer
Study | Cancer | Treatment | Age (range) | Times of AMH measurement | Number of patients | Conclusions about AMH follow up |
|---|---|---|---|---|---|---|
Broughman, 2012 [54] | Different type of cancer | Different protocols (low/ medium/high gonadotoxic protocols) | 4,4 (0,3-15) | Before CT, after each CT course, between 2 and 12 months post CT, >12 months post CT | 22 (9 high gonadotoxic protocol, 13 medium or low gonadotoxic protocol) | No difference between protocols regarding the depletion phase: |
-Significant fall of AMH levels from the third cycle of CT in all protocols. | ||||||
-Undetectable values of AMH in most patients at the end of CT. | ||||||
Different recovery phases according to protocol: | ||||||
-Very low or undetectable AMH levels in the high gonadotoxic group more than 12 months post CT. | ||||||
-Return to pre-treatment AMH values as soon as the 6th month of follow-up in the medium/low group risk. | ||||||
Mörse, 2013 [55] | Different type of cancer | Different protocols | 9,5 (4,5-16,5) | Before CT, Every 3 month during and after CT | 34 (27 alkylating protocol) | No difference between protocols regarding the depletion phase: |
-Significant fall of AMH levels 3 months after initiation of CT. | ||||||
Different recovery phases according to protocol: | ||||||
-Very low or undetectable AMH levels in the group with irradiation below the diaphragm and/or stem cell transplantation 18 month post follow-up. | ||||||
-Return to pre-treatment or higher AMH values as soon as the 15th month of follow-up in acute lymphatic leukemia group. |